| Rheumatoid Arthritis
Kineret vs Olumiant
Side-by-side clinical, coverage, and cost comparison for rheumatoid arthritis.Deep comparison between: Kineret vs Olumiant with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOlumiant has a higher rate of injection site reactions vs Kineret based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Olumiant but not Kineret, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kineret
Olumiant
At A Glance
SC injection
Daily
IL-1 receptor antagonist
Oral
Once daily
JAK inhibitor
Indications
- Rheumatoid Arthritis
- Chronic Infantile Neurological, Cutaneous, and Articular Syndrome
- INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY
- Rheumatoid Arthritis
- COVID-19 Virus Disease
- Alopecia Areata
Dosing
Rheumatoid Arthritis 100 mg/day SC; administer every other day in severe renal insufficiency or ESRD (creatinine clearance <30 mL/min).
Chronic Infantile Neurological, Cutaneous, and Articular Syndrome Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; once daily or split into twice daily; administer every other day in severe renal insufficiency or ESRD.
INTERLEUKIN 1 RECEPTOR ANTAGONIST DEFICIENCY Starting dose 1-2 mg/kg/day SC; titrate in 0.5 to 1 mg/kg increments to a maximum of 8 mg/kg/day; administer every other day in severe renal insufficiency or ESRD.
Rheumatoid Arthritis 2 mg once daily orally, with or without food; may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
COVID-19 Virus Disease 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.
Alopecia Areata 2 mg once daily orally; increase to 4 mg once daily if response is not adequate; reduce back to 2 mg once daily when adequate response is achieved.
Contraindications
- Known hypersensitivity to E. coli-derived proteins, anakinra, or any components of the product
—
Adverse Reactions
Most common (>=5%) Injection site reaction, worsening of RA, upper respiratory tract infections, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, abdominal pain
Serious Serious infections (cellulitis, pneumonia, bone and joint infections), neutropenia (particularly in combination with TNF blocking agents), lymphoma, other malignancies
Postmarketing Transaminase elevations, non-infectious hepatitis, thrombocytopenia (including severe), DRESS, injection site amyloid deposits
Most common (>=1%) Upper respiratory tract infections, nausea, herpes simplex, herpes zoster, acne, hyperlipidemia, urinary tract infections, headache, fatigue, folliculitis, lower respiratory tract infections, genital Candida infections, anemia, neutropenia, liver enzyme elevations, blood creatine phosphokinase increased, thrombocytosis, deep vein thrombosis, pulmonary embolism
Serious Serious infections, mortality, malignancy and lymphoproliferative disorders, major adverse cardiovascular events, thrombosis, hypersensitivity, gastrointestinal perforations, laboratory abnormalities
Postmarketing Drug hypersensitivity including rash, urticaria, and angioedema
Pharmacology
IL-1 receptor antagonist; anakinra is a recombinant human IL-1Ra that competitively inhibits IL-1alpha and IL-1beta binding to the interleukin-1 type I receptor (IL-1RI), blocking downstream inflammatory and immunological responses including cartilage degradation and bone resorption.
Baricitinib is a JAK inhibitor that selectively inhibits JAK1, JAK2, and TYK2, preventing phosphorylation and activation of STATs and thereby modulating cytokine signaling pathways involved in hematopoiesis and immune cell function.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kineret
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Olumiant
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Kineret
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (1/8)
Olumiant
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Kineret
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Olumiant
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Rheumatoid Arthritis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Olumiant Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KineretView full Kineret profile
OlumiantView full Olumiant profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.